A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
← catalyst calendarNCT07112378 · readout in 670 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →. With Sanofi.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
20estimated
Sites
12
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-10 | actual | When the study began enrolling |
| Primary completion | 2028-06-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-09 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Eosinophilic Esophagitis (EoE)
Intervention
- Drug: dupilumab — also filed as DUPIXENT®, REGN668, SAR231893
Primary outcome
what the primary-completion date above is the date OFIncidence of treatment-emergent Serious Adverse Events (SAEs)
measured Up to 24 Weeks
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed